University of Utah Hospitals & Clinics

Salt Lake City, Utah 84132

1 studies enrolling now · 13 studies all time

What they study most

Acute Respiratory Distress Syndrome, Adult, Adult Solid Tumor, Arginase I Deficiency, Breast Cancer, Cholangiocarcinoma, Chronic Cough, Colorectal Cancer, Fabry Disease, Head and Neck Neoplasms, Hyperargininemia, IPF, Infectious Pneumonia

Studies at this site

• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) — Recruiting now
• CREST-2 Long-term Observational Extension Study — Running, not enrolling
• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) — Running, not enrolling
• Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients — Completed
• Add-on Reparixin in Adult Patients With ARDS — Completed
• Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease — Completed
• Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia — Stopped early
• Description of Patients With Type 1 Diabetes Treated With Teplizumab — Completed
• Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy — Completed
• Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency — Completed
• Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) — Stopped early
• A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF — Stopped early
• Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia — Completed